Fundz

Harrow

Biotechnology, Healthcare, Health Care

Harrow (NASDAQ: HROW) is a growing leader in the ophthalmic healthcare market, dedicated to innovation and providing affordable, accessible medications. By closely listening to the needs of providers and patients, the company delivers high-quality products and services. Harrow’s commitment to excellence has made it one of the fastest-growing ophthalmic pharmaceutical companies in the United States

Key facts

Employees
282
Industries
Biotechnology, Healthcare, Health Care
Status
Public (HROW)
Website
harrow.com
LinkedIn
Company page

Recent activity at Harrow

  • : SEC 8-K (1.01): On October 1, 2026, Harrow, Inc. amended and restated its Asset Purchase Agreement with Viatris Inc. relating to the acquisition of TYRVAYA (varenicline solution) nasal spray 0.03 mg. This amendment includes that Viatris retains the rights to commercialize TYRVAYA in Japan, and the assets acquired by Harrow exclude those rights. Additionally, the parties have agreed to eliminate a post-Closing purchase price adjustment based on net working capital from the original agreement, modifying the financial terms of the acquisition significantly. The event date of October 1, 2026, reflects a critical change in the terms of the acquisition, impacting the strategic direction and financial arrangements of both companies involved.
  • : Harrow, Inc. Appoints Andrew R. Boll as Principal Accounting Officer
  • : SEC 8-K (5.02): Effective September 4, 2026, Randall E. Pollard has departed from his role as Chief Accounting Officer and principal accounting officer of Harrow, Inc. Following his departure, the Board of Directors appointed Andrew R. Boll, who is already serving as the President and Chief Financial Officer, to take over the responsibilities of the principal accounting officer. Notably, Mr. Boll will not receive any additional compensation for this new designation. This change may impact the financial reporting processes within the company, aligning the accounting leadership with existing company management.
  • : SEC 8-K (7.01): This filing is a Regulation FD Disclosure by Harrow, Inc., which includes a presentation that may be used by the Company’s management during its earnings call, at investor conferences, and at various meetings. Key documents attached, including Exhibits 99.1 and 99.2, comprise a press release and a letter to stockholders, both dated August 10, 2026. This presentation and the associated disclosures come at a critical time as they aim to engage current and potential investors, ensuring transparency of ongoing company operations and performance. The disclosures emphasize the Company's commitment to maintaining open communication with its stakeholders.
  • : SEC 8-K (1.01): On August 3, 2026, Harrow, Inc. entered into an Asset Purchase Agreement with Viatris Inc. to acquire the global rights to TYRVAYA®, a nasal spray indicated for dry eye disease. The acquisition includes various assets such as regulatory approvals and intellectual property, with an initial payment of $30 million in cash and up to $70 million in potential contingent milestone payments based on sales performance. The Company plans to close the deal in the second half of 2026, subject to customary conditions, and will also enter into ancillary agreements, including a transition services agreement. The transaction may impact Harrow’s product portfolio and market presence in the ophthalmic space significantly.
  • : SEC 8-K (7.01):
  • : SEC 8-K (7.01): The filing pertains to Item 7.01, Regulation FD Disclosure, which includes a corporate presentation by Harrow, Inc. to be utilized by management during earnings calls and investor conferences. The presentation and associated documents (Exhibits 99.1, 99.2, and 99.3) were issued on May 11, 2026. This filing is significant as it informs stakeholders about recent developments and financial results, enhancing transparency and communication with investors. The inclusion of a letter to stockholders and press release illustrates the company's strategic efforts to keep its investors informed and engaged during this period.
  • : SEC 8-K (1.01): On March 24, 2026, Harrow, Inc. entered into a Purchase Agreement with BTIG, LLC, involving the offer and sale of $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030. The Purchase Agreement includes typical representations, warranties, and covenants, and requires the Company to indemnify the Initial Purchasers against certain liabilities. Additionally, on March 27, 2026, a First Supplemental Indenture was executed with U.S. Bank Trust Company, under which the New Notes will be treated as part of an existing series of notes originally issued on September 12, 2025. The New Notes will have substantially the same terms as the Existing Notes, enhancing the Company's debt structure while increasing its financial obligations.
  • : SEC 8-K (8.01): On March 24, 2026, Harrow, Inc. announced the pricing of its offering of $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030 in a private offering. This Offering is targeted towards qualified institutional buyers in the U.S. and certain non-U.S. persons outside the U.S. The New Notes will be treated as a single series with the Existing Notes issued on September 12, 2025, sharing the same terms except for the issuance date and issue price. The announcement signifies Harrow's strategy to enhance its capital structure through these additional notes, which are structured under Regulation S for international transactions.
  • : SEC 8-K (8.01): Harrow, Inc. announced on March 24, 2026, the launch of an offer to sell $50.0 million of additional 8.625% Senior Notes due 2030 in a private offering. This offering is aimed at qualified institutional buyers in the U.S. and certain non-U.S. persons outside the U.S. The new notes will be issued under the same indenture as the existing $250 million notes issued on September 12, 2025, and will serve general corporate purposes, including funding product development and strategic initiatives. There is no guarantee that the offering will proceed as planned, and the Company may ultimately decide not to pursue it. The information is encapsulated in a press release, attached as Exhibit 99.1 of the filing.

Harrow funding history

DateRoundAmount
May 2021Venture$10.7M
Dec 2016Venture$10.1M

Leadership

  • R Horn, Director
  • Robert Kammer, Director
  • Teresa Sparks, Director
  • Richard Lindstrom, Director
  • Anthony Principi, Director
  • Stephen Austin, Director
  • Richard Lindstrom, Director
  • Robert Kammer, Director
  • Mark Baum, Executive Officer, Director
  • Arthur Chan, Vice President Medical Affairs
  • Sanjay Samudre, Senior Vice President and GM Manufacturing Operations
  • Randall E. Pollard, Chief Accounting Officer

Verified email and direct lines for Harrow’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Harrow in the news

Companies similar to Harrow

About Harrow: questions and answers

What does Harrow do?

Harrow (NASDAQ: HROW) is a growing leader in the ophthalmic healthcare market, dedicated to innovation and providing affordable, accessible medications. By closely listening to the needs of providers and patients, the company delivers high-quality products and services. Harrow’s commitment to excellence has made it one of the fastest-growing ophthalmic pharmaceutical companies in the United States

How many employees does Harrow have?

Harrow has about 282 employees.

Has Harrow raised funding?

Yes. Fundz has recorded 2 funding events for Harrow. The most recent, $10.7M, was in May 2021.

Who leads Harrow?

Arthur Chan is a Vice President Medical Affairs at Harrow.

What is the latest news on Harrow?

On Oct 01, 2026, SEC 8-K (1.01): On October 1, 2026, Harrow, Inc. amended and restated its Asset Purchase Agreement with Viatris Inc. relating to the acquisition of TYRVAYA (varenicline solution) nasal spray 0.03 mg. This amendment includes that Viatris retains the rights to commercialize TYRVAYA in Japan, and the a

Is Harrow a public company?

Yes. Harrow is publicly traded under the ticker HROW.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Harrow across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.